Edge Therapeutics (NASDAQ:EDGE) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Saturday.

EDGE has been the subject of a number of other research reports. Zacks Investment Research raised Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Monday, November 6th. Credit Suisse Group reiterated an “outperform” rating and issued a $17.00 target price on shares of Edge Therapeutics in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $20.00.

Edge Therapeutics (EDGE) opened at $12.40 on Friday. The company has a market capitalization of $382.65 and a PE ratio of -7.95. Edge Therapeutics has a 52 week low of $7.30 and a 52 week high of $12.70. The company has a debt-to-equity ratio of 0.20, a current ratio of 8.34 and a quick ratio of 8.34.

Edge Therapeutics (NASDAQ:EDGE) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.37) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.11. equities analysts expect that Edge Therapeutics will post -1.7 EPS for the current year.

In other Edge Therapeutics news, CEO Brian A. Leuthner sold 2,500 shares of Edge Therapeutics stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $10.92, for a total value of $27,300.00. Following the transaction, the chief executive officer now owns 102,736 shares in the company, valued at $1,121,877.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Brian A. Leuthner sold 5,000 shares of Edge Therapeutics stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $10.11, for a total value of $50,550.00. Following the completion of the transaction, the insider now owns 87,736 shares in the company, valued at approximately $887,010.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,361 shares of company stock worth $292,035. Company insiders own 36.19% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in EDGE. Voya Investment Management LLC bought a new position in Edge Therapeutics in the second quarter valued at about $106,000. Russell Investments Group Ltd. grew its position in Edge Therapeutics by 16.9% in the second quarter. Russell Investments Group Ltd. now owns 11,959 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 1,733 shares during the last quarter. Trexquant Investment LP bought a new position in Edge Therapeutics in the third quarter valued at about $130,000. Wells Fargo & Company MN grew its position in Edge Therapeutics by 44.4% in the third quarter. Wells Fargo & Company MN now owns 17,249 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 5,307 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Edge Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,114 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 3,764 shares during the last quarter. Hedge funds and other institutional investors own 50.26% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/01/21/edge-therapeutics-edge-stock-rating-upgraded-by-bidaskclub-2.html.

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.